ENDRA LIFE SCIEN.DL-,0001

ENDRA Life Sciences has been notified by NASDAQ that its reported shareholders' equity of USD 2,260,120 for the fiscal year ending 31 December 2025 is below the required minimum of USD 2,500,000, endangering continued listing. The company intends to timely request a hearing with the NASDAQ Hearings Panel, which would temporarily suspend delisting actions, and is evaluating options to restore compliance. The board is also reviewing strategic alternatives to enhance shareholder value; however, successful restoration of listing requirements or a successful appeal is not guaranteed. » More on de.investing.com

At the annual general meeting, shareholders voted to increase the authorized share capital from 20 million to 1,000 million shares; the Delaware filing became effective on December 10. Four directors were elected, executive compensation was approved on an advisory basis, and RBSM LLP was confirmed as auditor for 2025; a motion to indemnify officers was rejected. ENDRA also reported progress on the TAEUS liver device, a private placement of about $4.9 million, and initiatives in digital assets (HYPE-token staking) with security measures provided by Anchorage. » More on de.investing.com

ENDRA Life Sciences' stock dropped about 10% after a feasibility study showed the TAEUS device closely matched the gold-standard MRI-PDFF in thermoacoustic measurement of liver fat at critical thresholds (12–17% and 20–22%). For 12–17% the study reported PPV 100%, NPV 94% and accuracy 95%; for 20–22% PPV was 90%, NPV 94% and accuracy 94%. ENDRA positions the device as a low-cost alternative to MRI-PDFF (expected cost < $200 vs. > $2,500 for MRI) for patient stratification and study monitoring in MASLD and obesity. A second feasibility study is underway in London, Ontario, and the company plans FDA discussions in 2026 on the design of a pivotal (De Novo) study. » More on de.investing.com